Read More

AbbVie Announced Provincial Reimbursement for RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan

AbbVie (NYSE: ABBV), today announced that RINVOQ is now listed as a special authorization medication or exception medication status on the formularies of Alberta1, New Brunswick2, Ontario3, Quebec4 and Saskatchewan5 for the treatment of adults with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

ABBV

Read More

AbbVie Earlier Announced European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn’s Disease

AbbVie (NYSE: ABBV) announced the European Commission (EC) approved SKYRIZI® (risankizumab, 600 mg intravenous [IV] induction and 360 mg subcutaneous [SC] maintenance therapy) as the first specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease who have had in

ABBV

Read More

Genmab Announces FDA Acceptance For Priority Review Biologics License Application For Epcoritamab For The Treatment Of Relapsed/Refractory Large B-Cell Lymphoma

Epcoritamab BLA accepted for FDA Priority review; FDA action date is May 21, 2023 Epcoritamab could become the first subcutaneous bispecific antibody approved for the treatment of LBCL BLA submission supported by Epcoritamab BLA accepted for FDA Priority review; FDA action date is May 21, 2023

ABBV